LIV-1 (SLC39A6)
LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Zinc transporter of the ZIP family (SLC39A6) that localises to the plasma membrane, imports zinc and promotes EMT via STAT3/Snail; transcriptionally induced by oestrogen (hence LIV-1, from ER+ breast cancer lines).
- Breast cancer (>90% HR+, ~70% TNBC)
- Prostate cancer
- Cervical, melanoma, pancreatic cancer (subsets)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Key papers and the live literature
Preprints →Query for this target: (TITLE:"LIV-1" OR ABSTRACT:"LIV-1" OR TITLE:"SLC39A6" OR ABSTRACT:"SLC39A6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LIV-1 (SLC39A6), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/liv1.json. Licence CC BY 4.0.